中国实用神经疾病杂志Issue(12)：3-5,3.
尤瑞克林联合依达拉奉治疗急性大面积脑梗死临床研究
The clinical study of urinarykallid combined with edaravone in the treatment of acute massive cerebral infarc-tion
李巧薇 1李丽娟 1林耀波 1谭少华1
作者信息
- 1. 广州市番禺中心医院神经内科 番禺 511400
- 折叠
摘要
Abstract
Objective To observe the effect and safety of urinarykallid combined with edaravone in treating acute massive cerebral infarction(AMCI). Methods 180 patients with AMCI were randomly divided into 3 groups:control group(n=60) , treatment group A(n=60) and treatment group B(n=60). Besides a basic 14‐day therapy ,patients in treatment group A were given edaravone ,treatment group B received urinarykallid based on treatment group A. We recorded the change of CRP ,Na‐tional Institutes of Health Stroke Scale(NlHSS) scores and Barthelindex score(BI) before treatment and after 14‐and 90‐day treatment.Results After 14-day treatment ,The CRP of group B decreased more significantly than that of group A and the contol group(P<0.05);And likewise ,the lower NIHSS scores and the higher BI scores in group B (P<0.05). All groups had no severe adverse events in the whole period. Conclusion Urinarykallid combined with edaravone in the treatment of acute massive cerebral infarction were proved to be effective and safe.关键词
尤瑞克林/依达拉奉/急性大面积脑梗死/C反应蛋白Key words
U rinary Kallidinogenage/Edaravone/Acute massive cerebral infarction/CRP分类
医药卫生引用本文复制引用
李巧薇,李丽娟,林耀波,谭少华..尤瑞克林联合依达拉奉治疗急性大面积脑梗死临床研究[J].中国实用神经疾病杂志,2015,(12):3-5,3.
